Immatics (IMTX) News Today $7.80 -0.01 (-0.13%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesNovember 20 at 10:27 PM | finance.yahoo.comImmatics price target lowered to $15 from $16 at BofANovember 20 at 12:17 PM | markets.businessinsider.comJefferies Releases a Buy Rating on Immatics (IMTX)November 20 at 12:17 PM | markets.businessinsider.comIs Immatics N.V. (IMTX) the Best German Stock to Buy Now?November 20 at 12:17 PM | msn.comImmatics (NASDAQ:IMTX) Given New $15.00 Price Target at Bank of AmericaNovember 20 at 4:05 AM | americanbankingnews.comImmatics (NASDAQ:IMTX) Price Target Cut to $15.00 by Analysts at Bank of AmericaBank of America lowered their price target on Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday.November 19 at 12:53 PM | marketbeat.comImmatics price target lowered to $18 from $19 at LeerinkNovember 18 at 7:10 PM | markets.businessinsider.comImmatics Sees Revenue Surge Despite R&D ExpensesNovember 18 at 2:08 PM | markets.businessinsider.comImmatics announces clinical data on TCER IMA402 targeting PRAMENovember 18 at 2:08 PM | markets.businessinsider.comImmatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMENovember 18 at 7:00 AM | globenewswire.comImmatics (NASDAQ:IMTX) Reaches New 1-Year Low - Here's WhyImmatics (NASDAQ:IMTX) Reaches New 52-Week Low - Here's What HappenedNovember 14, 2024 | marketbeat.comImmatics’ Promising Immunotherapy Developments Bolster Jonathan Chang’s Buy RatingNovember 13, 2024 | markets.businessinsider.comImmatics Unveils Promising TCR-T Therapy DevelopmentsNovember 9, 2024 | markets.businessinsider.comImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMENovember 8, 2024 | globenewswire.comPositive Outlook for Immatics Due to Promising Clinical Trial Results and Manageable Safety ProfilesNovember 7, 2024 | markets.businessinsider.comabrdn plc Invests $2.66 Million in Immatics (NASDAQ:IMTX)abrdn plc purchased a new position in Immatics (NASDAQ:IMTX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 232,900 shares of the company's stock, valued at approxNovember 4, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Short Interest UpdateImmatics (NASDAQ:IMTX - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 10,020,000 shares, an increase of 5.3% from the September 30th total of 9,520,000 shares. Based on an average daily trading volume, of 487,400 shares, the days-to-cover ratio is currently 20.6 days.October 31, 2024 | marketbeat.comImmatics N.V. (IMTX)October 26, 2024 | finance.yahoo.comImmatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%October 24, 2024 | finance.yahoo.comPerceptive Advisors LLC Reduces Stake in Immatics NVOctober 18, 2024 | finance.yahoo.comBuy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR TherapeuticsOctober 15, 2024 | markets.businessinsider.comImmatics (NASDAQ:IMTX) Sees Significant Decline in Short InterestImmatics (NASDAQ:IMTX - Get Free Report) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 9,520,000 shares, a decline of 11.9% from the September 15th total of 10,800,000 shares. Based on an average trading volume of 324,000 shares, the short-interest ratio is currently 29.4 days.October 15, 2024 | marketbeat.comBuy Rating Affirmed for IMTX on Strong Clinical Data and Attractive Valuation Post-Equity FinancingOctober 14, 2024 | markets.businessinsider.comCubist Systematic Strategies LLC Acquires Shares of 206,920 Immatics (NASDAQ:IMTX)Cubist Systematic Strategies LLC acquired a new stake in Immatics (NASDAQ:IMTX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 206,920 shares of the company's stock, valued at approximately $2,404,000. Cubist Systematic StrategieOctober 12, 2024 | marketbeat.comImmatics: A Promising TCR PipelineOctober 12, 2024 | seekingalpha.comImmatics Advances IMA203 to Phase 3 Trial in MelanomaOctober 11, 2024 | finance.yahoo.comImmatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's WhyImmatics (NASDAQ:IMTX) Sees Large Volume Increase - Here's What HappenedOctober 11, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comImmatics Reports Updated Phase 1b Data Of IMA203 In Melanoma PatientsOctober 11, 2024 | markets.businessinsider.comImmatics Announces Pricing of $150 Million Public OfferingOctober 10, 2024 | globenewswire.comWhy Is Cancer-Focused Immatics Stock Trading Lower On Thursday?October 10, 2024 | benzinga.comImmatics (NASDAQ:IMTX) Shares Gap Down - Time to Sell?Immatics (NASDAQ:IMTX) Shares Gap Down - Here's WhyOctober 10, 2024 | marketbeat.comImmatics Announces Proposed $150 Million Public OfferingOctober 10, 2024 | globenewswire.comImmatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 TrialOctober 10, 2024 | globenewswire.comImmatics N.V. (IMTX) Receives Buy Rating from AnalystsOctober 9, 2024 | msn.comImmatics’ Promising Pipeline and Buy Recommendation: A Comprehensive Analysis by Joseph CatanzaroOctober 8, 2024 | markets.businessinsider.comPiper Sandler Initiates Coverage of Immatics N.V. (IMTX) with Overweight RecommendationOctober 8, 2024 | msn.comImmatics (NASDAQ:IMTX) Shares Gap Up - Here's WhyImmatics (NASDAQ:IMTX) Shares Gap Up - Should You Buy?October 7, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Earns Overweight Rating from Analysts at Piper SandlerPiper Sandler assumed coverage on Immatics in a research report on Monday. They set an "overweight" rating and a $19.00 price objective for the company.October 7, 2024 | marketbeat.comImmatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024October 4, 2024 | globenewswire.comImmatics (NASDAQ:IMTX) Shares Down 4.4% Immatics (NASDAQ:IMTX) Shares Down 4.4%October 2, 2024 | marketbeat.comPerceptive Advisors LLC Has $93.96 Million Stock Holdings in Immatics (NASDAQ:IMTX)Perceptive Advisors LLC raised its holdings in Immatics (NASDAQ:IMTX - Free Report) by 76.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,086,159 shares of the company's stock after buying an additional 3,503,750 shares during the quaSeptember 30, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Invests $13.39 Million in Immatics (NASDAQ:IMTX)Frazier Life Sciences Management L.P. acquired a new position in shares of Immatics (NASDAQ:IMTX - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,152,456 shares of the company's stock, valued at approximately $13,392,September 29, 2024 | marketbeat.comAffinity Asset Advisors LLC Sells 50,000 Shares of Immatics (NASDAQ:IMTX)Affinity Asset Advisors LLC decreased its position in Immatics (NASDAQ:IMTX - Free Report) by 14.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company's stock after selling 50,000 shares duriSeptember 25, 2024 | marketbeat.comImmunocore Holdings plc (6YG.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comHighVista Strategies LLC Acquires New Shares in Immatics (NASDAQ:IMTX)HighVista Strategies LLC bought a new position in shares of Immatics (NASDAQ:IMTX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 77,821 shares of the company's stock, valSeptember 23, 2024 | marketbeat.comImmatics (IMTX): Short Seller Sentiment is Bearish On This ADR StockSeptember 23, 2024 | finance.yahoo.comImmatics to Post FY2024 Earnings of ($1.03) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMTX)Immatics (NASDAQ:IMTX - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of Immatics in a report issued on Monday, September 16th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share oSeptember 19, 2024 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Sold by Sofinnova Investments Inc.Sofinnova Investments Inc. cut its holdings in shares of Immatics (NASDAQ:IMTX - Free Report) by 63.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 796,704 shares of the company's stock after selling 1,366,942September 17, 2024 | marketbeat.comImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development UpdateSeptember 16, 2024 | globenewswire.com Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest. Click here to discover our #1 crypto for the market right now – poised for massive growth IMTX Media Mentions By Week IMTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMTX News Sentiment▼0.250.45▲Average Medical News Sentiment IMTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMTX Articles This Week▼122▲IMTX Articles Average Week Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rhythm Pharmaceuticals News Today Apellis Pharmaceuticals News Today ImmunityBio News Today PTC Therapeutics News Today MoonLake Immunotherapeutics News Today HUTCHMED News Today Agios Pharmaceuticals News Today Verona Pharma News Today Dyne Therapeutics News Today Edgewise Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
